Long-term ouabain administration produces 3 hypertension in rats

Christina M. Yuan, Paolo Manunta, John M. Hamlyn, Shanwan Chen, Erin Bohen, Jane Yeun, Francis J. Haddy, Motilal B. Pamnani

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Ouabain has recently been identified as an endogenous Na+-K+ pump inhibitor. We administered ouabain chronically to normotensive rats with varying degrees of reduced renal mass (RRM) and to normal two-kidney rats to see whether hypertension could be produced. Normal male Wistar rats and rats with 25%, 60%, and 70% RRM received ouabain (13.9 μg/kg per day IP) in normal saline for 4 weeks followed by ouabain (27.8 μg/kg per day IP) for 3 to 4 more weeks. Respective control animals received vehicle only. Blood pressure was recorded weekly by tail plethysmography. Animals received tap water and standard rat chow, except for 70% RRM rats, which received distilled water and sodium-free chow. After 6 to 8 weeks of treatment, with rats under thiobutabarbital anesthesia, direct blood pressure was determined. Plasma, tissue, and urinary ouabain levels were measured with a specific radioimmunoassay. Animals receiving ouabain developed significant increases in mean blood pressure compared with control animals (70% RRM, 147±4 vs 116±4 mm Hg; 60% RRM, 140±4 vs 107±3 mm Hg; 25% RRM, 131±5 vs 100±2 mm Hg; no RRM, 116±4 vs 98±5 mm Hg). Plasma ouabain levels measured 24 hours after the last ouabain dose were not different in animals receiving ouabain vs those receiving vehicle. However, kidney tissue ouabain levels were significantly greater (6.39±1.17 vs 2.36±0.52 μg/kg, P

Original languageEnglish
Pages (from-to)178-187
Number of pages10
JournalHypertension
Volume22
Issue number2
Publication statusPublished - Aug 1993

Fingerprint

Ouabain
Hypertension
Kidney
Blood Pressure
Plethysmography
Water
Radioimmunoassay
Tail
Wistar Rats
Anesthesia
Sodium

Keywords

  • Hypertension, renal
  • Na,K-ATPase
  • Ouabain
  • Sodium-potassium pump

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Yuan, C. M., Manunta, P., Hamlyn, J. M., Chen, S., Bohen, E., Yeun, J., ... Pamnani, M. B. (1993). Long-term ouabain administration produces 3 hypertension in rats. Hypertension, 22(2), 178-187.

Long-term ouabain administration produces 3 hypertension in rats. / Yuan, Christina M.; Manunta, Paolo; Hamlyn, John M.; Chen, Shanwan; Bohen, Erin; Yeun, Jane; Haddy, Francis J.; Pamnani, Motilal B.

In: Hypertension, Vol. 22, No. 2, 08.1993, p. 178-187.

Research output: Contribution to journalArticle

Yuan, CM, Manunta, P, Hamlyn, JM, Chen, S, Bohen, E, Yeun, J, Haddy, FJ & Pamnani, MB 1993, 'Long-term ouabain administration produces 3 hypertension in rats', Hypertension, vol. 22, no. 2, pp. 178-187.
Yuan CM, Manunta P, Hamlyn JM, Chen S, Bohen E, Yeun J et al. Long-term ouabain administration produces 3 hypertension in rats. Hypertension. 1993 Aug;22(2):178-187.
Yuan, Christina M. ; Manunta, Paolo ; Hamlyn, John M. ; Chen, Shanwan ; Bohen, Erin ; Yeun, Jane ; Haddy, Francis J. ; Pamnani, Motilal B. / Long-term ouabain administration produces 3 hypertension in rats. In: Hypertension. 1993 ; Vol. 22, No. 2. pp. 178-187.
@article{a224b9143c4443968096ef97389f8c00,
title = "Long-term ouabain administration produces 3 hypertension in rats",
abstract = "Ouabain has recently been identified as an endogenous Na+-K+ pump inhibitor. We administered ouabain chronically to normotensive rats with varying degrees of reduced renal mass (RRM) and to normal two-kidney rats to see whether hypertension could be produced. Normal male Wistar rats and rats with 25{\%}, 60{\%}, and 70{\%} RRM received ouabain (13.9 μg/kg per day IP) in normal saline for 4 weeks followed by ouabain (27.8 μg/kg per day IP) for 3 to 4 more weeks. Respective control animals received vehicle only. Blood pressure was recorded weekly by tail plethysmography. Animals received tap water and standard rat chow, except for 70{\%} RRM rats, which received distilled water and sodium-free chow. After 6 to 8 weeks of treatment, with rats under thiobutabarbital anesthesia, direct blood pressure was determined. Plasma, tissue, and urinary ouabain levels were measured with a specific radioimmunoassay. Animals receiving ouabain developed significant increases in mean blood pressure compared with control animals (70{\%} RRM, 147±4 vs 116±4 mm Hg; 60{\%} RRM, 140±4 vs 107±3 mm Hg; 25{\%} RRM, 131±5 vs 100±2 mm Hg; no RRM, 116±4 vs 98±5 mm Hg). Plasma ouabain levels measured 24 hours after the last ouabain dose were not different in animals receiving ouabain vs those receiving vehicle. However, kidney tissue ouabain levels were significantly greater (6.39±1.17 vs 2.36±0.52 μg/kg, P",
keywords = "Hypertension, renal, Na,K-ATPase, Ouabain, Sodium-potassium pump",
author = "Yuan, {Christina M.} and Paolo Manunta and Hamlyn, {John M.} and Shanwan Chen and Erin Bohen and Jane Yeun and Haddy, {Francis J.} and Pamnani, {Motilal B.}",
year = "1993",
month = "8",
language = "English",
volume = "22",
pages = "178--187",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Long-term ouabain administration produces 3 hypertension in rats

AU - Yuan, Christina M.

AU - Manunta, Paolo

AU - Hamlyn, John M.

AU - Chen, Shanwan

AU - Bohen, Erin

AU - Yeun, Jane

AU - Haddy, Francis J.

AU - Pamnani, Motilal B.

PY - 1993/8

Y1 - 1993/8

N2 - Ouabain has recently been identified as an endogenous Na+-K+ pump inhibitor. We administered ouabain chronically to normotensive rats with varying degrees of reduced renal mass (RRM) and to normal two-kidney rats to see whether hypertension could be produced. Normal male Wistar rats and rats with 25%, 60%, and 70% RRM received ouabain (13.9 μg/kg per day IP) in normal saline for 4 weeks followed by ouabain (27.8 μg/kg per day IP) for 3 to 4 more weeks. Respective control animals received vehicle only. Blood pressure was recorded weekly by tail plethysmography. Animals received tap water and standard rat chow, except for 70% RRM rats, which received distilled water and sodium-free chow. After 6 to 8 weeks of treatment, with rats under thiobutabarbital anesthesia, direct blood pressure was determined. Plasma, tissue, and urinary ouabain levels were measured with a specific radioimmunoassay. Animals receiving ouabain developed significant increases in mean blood pressure compared with control animals (70% RRM, 147±4 vs 116±4 mm Hg; 60% RRM, 140±4 vs 107±3 mm Hg; 25% RRM, 131±5 vs 100±2 mm Hg; no RRM, 116±4 vs 98±5 mm Hg). Plasma ouabain levels measured 24 hours after the last ouabain dose were not different in animals receiving ouabain vs those receiving vehicle. However, kidney tissue ouabain levels were significantly greater (6.39±1.17 vs 2.36±0.52 μg/kg, P

AB - Ouabain has recently been identified as an endogenous Na+-K+ pump inhibitor. We administered ouabain chronically to normotensive rats with varying degrees of reduced renal mass (RRM) and to normal two-kidney rats to see whether hypertension could be produced. Normal male Wistar rats and rats with 25%, 60%, and 70% RRM received ouabain (13.9 μg/kg per day IP) in normal saline for 4 weeks followed by ouabain (27.8 μg/kg per day IP) for 3 to 4 more weeks. Respective control animals received vehicle only. Blood pressure was recorded weekly by tail plethysmography. Animals received tap water and standard rat chow, except for 70% RRM rats, which received distilled water and sodium-free chow. After 6 to 8 weeks of treatment, with rats under thiobutabarbital anesthesia, direct blood pressure was determined. Plasma, tissue, and urinary ouabain levels were measured with a specific radioimmunoassay. Animals receiving ouabain developed significant increases in mean blood pressure compared with control animals (70% RRM, 147±4 vs 116±4 mm Hg; 60% RRM, 140±4 vs 107±3 mm Hg; 25% RRM, 131±5 vs 100±2 mm Hg; no RRM, 116±4 vs 98±5 mm Hg). Plasma ouabain levels measured 24 hours after the last ouabain dose were not different in animals receiving ouabain vs those receiving vehicle. However, kidney tissue ouabain levels were significantly greater (6.39±1.17 vs 2.36±0.52 μg/kg, P

KW - Hypertension, renal

KW - Na,K-ATPase

KW - Ouabain

KW - Sodium-potassium pump

UR - http://www.scopus.com/inward/record.url?scp=0027312742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027312742&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 178

EP - 187

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -